Advertisement
KMDA vs SGIOY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KMDA is a StrongBuy and SGIOY is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
KMDA’s FA Score shows that 0 FA rating(s) are green whileSGIOY’s FA Score has 0 green FA rating(s).
- KMDA’s FA Score: 0 green, 5 red.
- SGIOY’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
KMDA’s TA Score shows that 7 TA indicator(s) are bullish while SGIOY’s TA Score has 5 bullish TA indicator(s).
- KMDA’s TA Score: 7 bullish, 2 bearish.
- SGIOY’s TA Score: 5 bullish, 4 bearish.
Price Growth
KMDA (@Pharmaceuticals: Other) experienced а -3.12% price change this week, while SGIOY (@Pharmaceuticals: Other) price change was +7.70% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.10%. For the same industry, the average monthly price growth was +10.36%, and the average quarterly price growth was +30.06%.
Reported Earning Dates
KMDA is expected to report earnings on Aug 13, 2025.
SGIOY is expected to report earnings on Aug 04, 2025.
Industries' Descriptions
@Pharmaceuticals: Other (-0.10% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| KMDA | SGIOY | KMDA / SGIOY | |
| Capitalization | 306M | 12.4B | 2% |
| EBITDA | 22.4M | 242B | 0% |
| Gain YTD | 15.365 | 14.513 | 106% |
| P/E Ratio | 37.43 | 9.62 | 389% |
| Revenue | 143M | 427B | 0% |
| Total Cash | 55.6M | 563B | 0% |
| Total Debt | 8.82M | 9.41B | 0% |
KMDA | SGIOY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 8 | 64 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 70 Overvalued | 34 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 47 | 51 | |
P/E GROWTH RATING 1..100 | 42 | 59 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SGIOY's Valuation (34) in the null industry is somewhat better than the same rating for KMDA (70) in the Biotechnology industry. This means that SGIOY’s stock grew somewhat faster than KMDA’s over the last 12 months.
SGIOY's Profit vs Risk Rating (100) in the null industry is in the same range as KMDA (100) in the Biotechnology industry. This means that SGIOY’s stock grew similarly to KMDA’s over the last 12 months.
SGIOY's SMR Rating (100) in the null industry is in the same range as KMDA (100) in the Biotechnology industry. This means that SGIOY’s stock grew similarly to KMDA’s over the last 12 months.
KMDA's Price Growth Rating (47) in the Biotechnology industry is in the same range as SGIOY (51) in the null industry. This means that KMDA’s stock grew similarly to SGIOY’s over the last 12 months.
KMDA's P/E Growth Rating (42) in the Biotechnology industry is in the same range as SGIOY (59) in the null industry. This means that KMDA’s stock grew similarly to SGIOY’s over the last 12 months.
| KMDA | SGIOY | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 71% |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 58% |
| Momentum ODDS (%) | 2 days ago 71% | 2 days ago 67% |
| MACD ODDS (%) | 4 days ago 70% | 2 days ago 59% |
| TrendWeek ODDS (%) | 2 days ago 68% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 69% | 2 days ago 69% |
| Advances ODDS (%) | 9 days ago 66% | 2 days ago 65% |
| Declines ODDS (%) | 11 days ago 67% | 9 days ago 58% |
| BollingerBands ODDS (%) | 2 days ago 75% | 2 days ago 65% |
| Aroon ODDS (%) | 2 days ago 70% | N/A |
Advertisement
SGIOY and
Correlation & Price change
A.I.dvisor indicates that over the last year, SGIOY has been loosely correlated with TAK. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if SGIOY jumps, then TAK could also see price increases.
| Ticker / NAME | Correlation To SGIOY | 1D Price Change % | ||
|---|---|---|---|---|
| SGIOY | 100% | +1.59% | ||
| TAK - SGIOY | 40% Loosely correlated | +0.35% | ||
| ESAIY - SGIOY | 36% Loosely correlated | +2.87% | ||
| KMDA - SGIOY | 27% Poorly correlated | -0.58% | ||
| SCYX - SGIOY | 23% Poorly correlated | -3.58% | ||
| SUPN - SGIOY | 22% Poorly correlated | -1.72% | ||
More | ||||